These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7733838)

  • 1. Double-blind crossover study with levorotatory form of hydroxytryptophan in patients with degenerative cerebellar diseases.
    Wessel K; Hermsdörfer J; Deger K; Herzog T; Huss GP; Kömpf D; Mai N; Schimrigk K; Wittkämper A; Ziegler W
    Arch Neurol; 1995 May; 52(5):451-5. PubMed ID: 7733838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study.
    Trouillas P; Serratrice G; Laplane D; Rascol A; Augustin P; Barroche G; Clanet M; Degos CF; Desnuelle C; Dumas R
    Arch Neurol; 1995 May; 52(5):456-60. PubMed ID: 7733839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing.
    Trouillas P; Brudon F; Adeleine P
    Arch Neurol; 1988 Nov; 45(11):1217-22. PubMed ID: 3190503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind crossover study with physostigmine in patients with degenerative cerebellar diseases.
    Wessel K; Langenberger K; Nitschke MF; Kömpf D
    Arch Neurol; 1997 Apr; 54(4):397-400. PubMed ID: 9109740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan].
    Trouillas P; Garde A; Robert JM; Adeleine P
    C R Seances Acad Sci III; 1981 Jan; 292(1):119-22. PubMed ID: 6786764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, crossover, placebo-controlled clinical trial with L-acetylcarnitine in patients with degenerative cerebellar ataxia.
    Sorbi S; Forleo P; Fani C; Piacentini S
    Clin Neuropharmacol; 2000; 23(2):114-8. PubMed ID: 10803803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of fast single-joint and multijoint movements in cerebellar cortical atrophy: failure of L-hydroxytryptophan to improve cerebellar ataxia.
    Manto M; Hildebrand J; Godaux E; Roland H; Blum S; Jacquy J
    Arch Neurol; 1997 Oct; 54(10):1192-4. PubMed ID: 9341562
    [No Abstract]   [Full Text] [Related]  

  • 8. [Regression of the cerebellar syndrome under long-term administration of 5-HTP or the combination of 5-HTP and benserazide. 26 cases quantified and treated using computer methods].
    Trouillas P; Garde A; Robert JM; Renaud B; Adeleine P; Bard J; Brudon F
    Rev Neurol (Paris); 1982; 138(5):415-35. PubMed ID: 6983101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of buspirone, a serotonergic 5-HT-1A agonist in cerebellar ataxia: a pilot study. Preliminary communication].
    Trouillas P; Xie J; Getenet JC; Adeleine P; Nighoghossian N; Honnorat J; Riche G; Derex L
    Rev Neurol (Paris); 1995 Dec; 151(12):708-13. PubMed ID: 8787101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buspirone, a serotonergic 5-HT1A agonist, is active in cerebellar ataxia. A new fact in favor of the serotonergic theory of ataxia.
    Trouillas P; Xie J; Adeleine P
    Prog Brain Res; 1997; 114():589-99. PubMed ID: 9193169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological treatments of cerebellar ataxia.
    Ogawa M
    Cerebellum; 2004; 3(2):107-11. PubMed ID: 15233578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide.
    Trouillas P
    Ital J Neurol Sci; 1984 Sep; 5(3):253-66. PubMed ID: 6334064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hereditary ataxia with the levorotatory form of hydroxytryptophan.
    Currier RD; Collins GM; Subramony SH; Haerer AF
    Arch Neurol; 1995 May; 52(5):440-1. PubMed ID: 7733833
    [No Abstract]   [Full Text] [Related]  

  • 14. Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis.
    Monaca-Charley C; Stojkovic T; Duhamel A; De Seze J; Ferriby D; Vermersch P
    J Neurol; 2003 Oct; 250(10):1190-4. PubMed ID: 14586600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Acetyl-DL-Leucine in Certain Types of Cerebellar Ataxia: The ALCAT Randomized Clinical Crossover Trial.
    Feil K; Adrion C; Boesch S; Doss S; Giordano I; Hengel H; Jacobi H; Klockgether T; Klopstock T; Nachbauer W; Schöls L; Steiner KM; Stendel C; Timmann D; Naumann I; Mansmann U; Strupp M;
    JAMA Netw Open; 2021 Dec; 4(12):e2135841. PubMed ID: 34905009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choline chloride in the treatment of cerebellar and spinocerebellar ataxia.
    Livingstone IR; Mastaglia FL; Pennington RJ; Skilbeck C
    J Neurol Sci; 1981 May; 50(2):161-74. PubMed ID: 7229661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebellar ataxia.
    Klein P
    Arch Neurol; 1989 Nov; 46(11):1166. PubMed ID: 2818245
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial.
    Feil K; Adrion C; Teufel J; Bösch S; Claassen J; Giordano I; Hengel H; Jacobi H; Klockgether T; Klopstock T; Nachbauer W; Schöls L; Stendel C; Uslar E; van de Warrenburg B; Berger I; Naumann I; Bayer O; Müller HH; Mansmann U; Strupp M
    BMC Neurol; 2017 Jan; 17(1):7. PubMed ID: 28068987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic trial in a family with late cerebellar atrophy].
    Gracia Naya M; Pina Latorre MA
    Neurologia; 1991 May; 6(5):188-9. PubMed ID: 1908256
    [No Abstract]   [Full Text] [Related]  

  • 20. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy.
    Trouillas P; Xie J; Adeleine P; Michel D; Vighetto A; Honnorat J; Dumas R; Nighoghossian N; Laurent B
    Arch Neurol; 1997 Jun; 54(6):749-52. PubMed ID: 9193210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.